Neurogene to Participate in Upcoming Conferences
February 24 2025 - 7:30AM
Business Wire
Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded
to bring life-changing genetic medicines to patients and families
affected by rare neurological diseases, today announced that
Company management will participate in the following
conferences:
TD Cowen 45th Annual Health Care Conference Format:
Management will participate in a fireside chat and investor
meetings Date: Monday, March 3 at 9:50 a.m. ET
Leerink Global Healthcare Conference Format: Management
will participate in a fireside chat and investor meetings Date:
Monday, March 10 at 1:00 p.m. ET
Stifel Virtual CNS Forum Format: Management will
participate in a fireside chat Date: Wednesday, March 19 at 9:30
a.m. ET
Live webcasts of the fireside chats will be accessible from the
Investor Relations section of Neurogene’s website under events,
where a replay of the events will also be available for a limited
time.
About Neurogene
The mission of Neurogene is to treat devastating neurological
diseases to improve the lives of patients and families impacted by
these rare diseases. Neurogene is developing novel approaches and
treatments to address the limitations of conventional gene therapy
in central nervous system disorders. This includes selecting a
delivery approach to maximize distribution to target tissues and
designing products to maximize potency and purity for an optimized
efficacy and safety profile. The Company’s novel and proprietary
EXACT transgene regulation platform technology allows for the
delivery of therapeutic levels while limiting transgene toxicity
associated with conventional gene therapy. Neurogene has
constructed a state-of-the-art gene therapy manufacturing facility
in Houston, Texas. CGMP production of NGN-401 was conducted in this
facility and will support pivotal clinical development activities.
For more information, visit www.neurogene.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250224253404/en/
Company Contact: Cara Mayfield Vice President, Corporate
Affairs cara.mayfield@neurogene.com
Investor Contact: Melissa Forst Argot Partners
Neurogene@argotpartners.com
Neurogene (NASDAQ:NGNE)
Historical Stock Chart
From Jan 2025 to Feb 2025
Neurogene (NASDAQ:NGNE)
Historical Stock Chart
From Feb 2024 to Feb 2025